The main findings of this study were that 29.8% of the patients with cervical cancer harbored oncogenic mutations in the 16 genes assessed, and the mutation rates of PIK3CA/PTEN, RTK and RAS were 15.1%, 10.2%, and 6.3%, respectively. This evidence concerns the gene PIK3CA and cervical cancer.